Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03367156 · ClinicalTrials.gov registry record · Phase 2
Dexamethasone in Controlling Dyspnea in Patients With Cancer
A Phase 2 study of Malignant Neoplasm and Dyspnea, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 3
- Study locations
NCT03367156 is a Phase 2 study of Malignant Neoplasm and Dyspnea that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 135 participants, below the 511-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (74% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT03367156, a Phase 2 study of Malignant Neoplasm and Dyspnea, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial studies how well dexamethasone works in controlling dyspnea in patients with cancer. Dexamethasone may help control dyspnea (shortness of breath) and improve lung function and quality of life in cancer patients.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Questionnaire Administration
- DRUG Dexamethasone
Study Locations (3)
Texas
- Lyndon B. Johnson Hospital - Houston
- Harris Health System Settegast Health Center - Houston
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2017-12-04 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03367156
The ClinicalTrials.gov registry entry for NCT03367156 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 511-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (74% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Malignant Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03367156 reports 3 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03367156 about?
NCT03367156 is a clinical study titled "Dexamethasone in Controlling Dyspnea in Patients With Cancer". This phase II trial studies how well dexamethasone works in controlling dyspnea in patients with cancer. Dexamethasone may help control dyspnea (shortness of breath) and improve lung function and quality of life in cancer patients.
What is the current status of trial NCT03367156?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2017-12-04. Estimated completion is 2025-12-31.
What conditions does trial NCT03367156 study?
This clinical trial studies the following conditions: Malignant Neoplasm, Dyspnea.
What interventions are being tested in trial NCT03367156?
The interventions under investigation include: Placebo (OTHER), Questionnaire Administration (OTHER), Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT03367156?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03367156 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Intraoperative Tumor Margin Identification With ICG Dye Imaging
RECRUITING · Phase 2
-
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
RECRUITING · Phase 2
-
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
RECRUITING · Phase 2
-
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.